格雷夫斯病患者考虑长期抗甲状腺药物治疗的临床决策路径
抗甲状腺药物(ATD)是全球多数格雷夫斯甲状腺功能亢进症患者的首选治疗,但常规12至18个月疗程停药后复发非常常见。近二十年研究显示长期ATD(LT-ATD)维持甲状腺功能正常有效且安全,血清TSH受体抗体在ATD治疗5至6年前可能不会永久下降,临床试验显示ATD治疗≥5年可使多数患者缓解。本文讨论常规ATD停药的最佳时机、复发性甲亢的管理决策、LT-ATD的恰当管理,并通过4个决策场景提出终身ATD治疗的建议。
要点
- 常规12至18个月ATD停药后甲亢复发非常常见。
- 长期ATD治疗维持甲状腺功能正常有效且安全。
- ATD治疗≥5年可使多数格雷夫斯甲亢患者缓解。
核心结论
- 长期ATD治疗在维持甲状腺功能正常方面有效且安全,ATD治疗≥5年可使多数格雷夫斯甲亢患者缓解。
研究设计与样本
- 本文为临床决策综述,通过讨论格雷夫斯病患者的4个决策场景提出终身ATD治疗的建议。
主要发现
- 常规 arbitrarily 选择的12至18个月ATD治疗后停药,甲亢复发非常常见。
- 血清TSH受体抗体在ATD治疗5至6年前可能不会永久下降。
- 临床试验显示ATD治疗≥5年可使多数格雷夫斯甲亢患者缓解。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antithyroid drugs (ATD) are the treatment of choice for the majority of patients with Graves' hyperthyroidism worldwide. However, relapse of hyperthyroidism after withdrawal of arbitrarily chosen conventional 12 to 18 months of therapy is very common. In the last 2 decades, many studies have shown that treatment with long-term ATD (LT-ATD) is effective and safe in the maintenance of euthyroidism. In addition, it has been reported that serum TSH receptor antibody may not decrease permanently before 5 to 6 years of ATD treatment, and clinical trials have shown that ≥5 years of ATD treatment is accompanied by remission in the majority of patients with Graves' hyperthyroidism. The objective of this article is to discuss the optimal time to withdraw of conventional ATD therapy, to illustrate the decision-making of the management of recurrent hyperthyroidism, to review the proper management of LT-ATD, and to generate suggestions for lifelong ATD treatment by discussing 4 scenarios of decision-making in patients with Graves' disease.
引用
- Azizi F, Mehran L, Abdi H, et al. Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves' Disease. J Clin Endocrinol Metab. 2024. PMID: 39018185. doi:10.1210/clinem/dgae456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。